Release Date: March 31, 2023
Expiration Date: March 31, 2024
Time to Complete Activity: 0.5 hour
Faculty
Guillermo Garcia-Manero, MD
McCredie Professor of Medicine
Vice Chair, Department of Leukemia
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
The University of Texas MD Anderson Cancer Center Houston, TX
Daniel A. Pollyea, MD, MS
Professor of Medicine, Division of Hematology
Clinical Director of Leukemia Services
Robert H. Allen, MD Endowed Chair in Hematology Research
University of Colorado School of Medicine Aurora, CO
Target Audience
This activity has been designed to address the educational needs of hematology/oncology physicians, pathologists, pharmacists, and oncology advanced practitioners. It may also benefit oncology nurses and other healthcare professionals who manage patients with myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML).
This activity is jointly provided by Paradigm Medical Communications, LLC and Educational Review Systems, Inc. In collaboration with The MDS Foundation.
Supporter Acknowledgment
This activity is supported by an independent educational grant from Gilead Sciences, Inc.
Program Overview
The management of MDS is evolving, with the publication and adoption of the International Prognostic Scoring System-Molecular (IPSS-M), which now includes molecular testing results for prognostication. In addition, the treatment of MDS is poised to change as well, as several emerging agents have demonstrated promising results in early phase trials and are now being evaluated in phase 3 studies. Given this, new questions have arisen about risk stratification and treatment selection now and in the future for higher-risk MDS. In addition, the high similarity between TP53-mutated MDS and AML suggests that they are a single entity that can be treated similarly. This interactive infographic will engage learners in a multimedia journey about the latest updates on the management of higher-risk MDS and the overlap between MDS and AML with mutated TP53.
Learning Objectives
Upon completion of this activity, participants should be able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Paradigm Medical Communications, LLC and Educational Review Systems, Inc. Paradigm Medical Communications, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 0.50 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Pharmacist Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 0.5 contact hour (0.05 CEU) submitted to CPE Monitor as early as 14 days after completion and no later than 60 days after completion. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-23-017-H01-P
This is a knowledge-based activity.
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Instructions for Participation
To receive a certificate of participation, participants must:
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Disclosure of Relevant Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
Guillermo Garcia-Manero, MD
Has no relevant financial relationships with ineligible companies to disclose.
Daniel A. Pollyea, MD, MS
Advisor: AbbVie Inc.; Aprea Therapeutics; Aptevo Therapeutics; Arcellx; Astellas Pharma US, Inc; AstraZeneca; BeiGene Inc.; BerGenBio ASA; Bristol-Myers Squibb Company; Daiichi Sankyo Company, Limited; Foghorn Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; HiberCell Inc; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc; Karyopharm; Kura Oncology, Inc; Link Pharma Chem Ltd; Magenta Therapeutics; Medivir AB; Novartis AG; Qihan Biotech Co, Ltd; Ryvu Therapeutics; Syndax; Syros Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd; Zentalis Pharmaceuticals
Research Funding: AbbVie Inc.; Bristol-Myers Squibb Company; Karyopharm; Teva Pharmaceutical Industries Ltd.
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Educational Review Systems, Inc staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
